ASCO Preview: Alecensa Bests Xalkori In Japan Head-To-Head

Chugai has unveiled new details of positive head-to-head Japanese clinical results for its breakthrough cancer therapy alectinib, which showed benefits over close rival crizotinib in lung cancer.